Clovis Oncology
CLVS
$0.08120
Share price
0.00%
Change (1 day)
-95.08%
Change (1 year)
Categories
Clovis Oncology (CLVS) - Cash on Hand
Cash on Hand as of September 2022 : $58.32 M
According to Clovis Oncology's latest financial reports the company has $58.32 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Clovis Oncology - Cash on Hand chart (from 2010 to 2022)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2021-12-31 | $0.14 B | -40.3% |
| 2020-12-31 | $0.24 B | -19.02% |
| 2019-12-31 | $0.29 B | -42.97% |
| 2018-12-31 | $0.52 B | -7.73% |
| 2017-12-31 | $0.56 B | 111.78% |
| 2016-12-31 | $0.26 B | -49.64% |
| 2015-12-31 | $0.52 B | 9.51% |
| 2014-12-31 | $0.48 B | 49.33% |
| 2013-12-31 | $0.32 B | 124.31% |
| 2012-12-31 | $0.14 B | 2.74% |
| 2011-12-31 | $0.14 B | 528.94% |
| 2010-12-31 | $22.29 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $22.92 B | 39,212.41% | 🇺🇸 USA |
 Pfizer PFE | $12.69 B | 21,659.26% | 🇺🇸 USA |
 AbbVie ABBV | $12.81 B | 21,875.31% | 🇺🇸 USA |
 Eli Lilly LLY | $2.92 B | 4,920.06% | 🇺🇸 USA |
 AstraZeneca AZN | $8.02 B | 13,653.43% | 🇬🇧 UK |
 BioMarin Pharmaceutical BMRN | $1.07 B | 1,741.24% | 🇺🇸 USA |